The reiteration of a Neutral rating and maintenance of a $24 price target by Wedbush suggests no significant short-term price movement is expected for Sage Therapeutics. The analyst's view likely reflects a balanced outlook on the company's prospects, without new catalysts to drive significant positive or negative sentiment.